novo nordisk weight loss

News

Novo Nordisk Gave Up Its Weight-Loss Gains

Novo Nordisk shares dip further as Wegovy gains nearly erased

Shares in Novo Nordisk fell as much as 6% on Friday before recovering some ground later in the session, extending recent losses that threaten to wipe out all the gains since the drugmaker launched its blockbuster weight-loss treatment Wegovy four years ago.

Bloomberg on MSN · 1d

How Novo Nordisk Gave Up Its Weight-Loss Gains

Novo took the active ingredient of Ozempic, semaglutide, and rebranded it as Wegovy to be used specifically for weight loss. Together, these blockbuster drugs made Novo the most valuable publicly listed company in Europe. At one point, its market capitalization was even bigger than the size of Denmark’s economy.

The Wall Street Journal on MSN · 3d

Novo Nordisk Shares Plummet as Competition Weighs on Sales

The pharmaceutical giant cut its guidance and said U.S. sales of Ozempic grew more slowly.

1don MSN

Eli Lilly Weight-Loss Drug Makes Cardio Advance. More Bad News for Novo Nordisk.

A Lilly study showed Mounjaro resulted in a lower risk of heart attacks and strokes in patients with diabetes compared with ...

2don MSN

Can Novo Nordisk’s New CEO Stop Rivals From Taking Over the Anti-Obesity Market?

Danish leader will face a challenging landscape among competitors ...

23hon MSN

Why Novo Nordisk Stock Bumped Higher on Friday

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...

23hon MSN

Trump’s Weight-Loss Experiment Could Aid Lilly, Novo. Cost Is Still a Problem.

The Washington Post reported the CMS is considering a plan that could allow Medicare plans to pay for the drugs.

Novo Nordisk A/S (NVO) Could Lose To Eli Lilly, Warns Jim Cramer

We recently published 10 Stocks That Jim Cramer Talked About. Novo Nordisk A/S (NYSE:NVO) is one of the stocks Jim Cramer ...

4don MSN

Wegovy maker Novo's profit warning triggers $70 billion share rout

Investors wiped $70 billion off Novo Nordisk's market value on Tuesday after the maker of weight-loss drug Wegovy issued a ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results